COVID-19 and tuberculosis in South Africa: A dangerous combination

To the Editor: There has been much speculation during the past week about the catastrophe that awaits once coronavirus disease 2019 (COVID-19) establishes itself in the poorest communities of South Africa (SA) and, importantly, in informal settlements. Evidence to date suggests that COVID-19 is efficiently passed from infected individuals via large droplets and hard-surface fomites. Given the housing density and shared toilet and tap facilities in informal settlements, interventions such as frequent hand washing, social distancing and self-isolation will be particularly difficult to achieve. In addition, the disproportionate burden of HIV has left many making dire predictions for the consequences to the people and the health system if, or more appropriately when, COVID-19 reaches these communities. In the wake of World TB Day, we would like to remind readers why tuberculosis (TB) is also an important and complex consideration for vulnerable populations in relation to COVID-19.

At the time of writing (24 March 2020), 554 cases of COVID-19 have been detected and reported in SA, largely among people aged 21 - 60 years. No deaths have yet been reported, and the majority of cases are still imported by people who have recently travelled. In the language of the day, the SA epidemic curve has just begun. Early data from China indicate that individuals most at risk for severe responses to COVID-19 are those aged >60 years and those with comorbidities such as chronic respiratory disease, hypertension, diabetes and cardiovascular disease. To date, COVID-19 has not been studied in low- and middle-income countries with endemic HIV. With an estimated 7.7 million people living with HIV in SA, concerns about the effect of COVID-19 on people with suppressed immune systems have largely dominated the conversation. Yet HIV is only one piece of the equation.

In SA, an estimated 301 000 people developed TB in 2019, nearly 60% of whom were also HIV-infected. It is unclear how COVID-19 may manifest itself in this population. Regardless of HIV status, people with undiagnosed pulmonary TB (PTB), those with drug-resistant TB or complex presentations such as disseminated forms, and those who have only just begun PTB treatment may be at increased risk for severe responses if they become infected with COVID-19. As seen with PTB and silicosis, combined pulmonary diseases can multiply the gravity of the situation. Moreover, common COVID-19 symptoms (cough, fever, and to a lesser degree, shortness of breath) overlap with PTB, which may make distinguishing between the two problematic for healthcare workers in high-burden communities. Although sputum production is a common feature of PTB, is less common among individuals with COVID-19, those with TB-HIV co-infection may not present with sputum production. It will be important for clinicians to stay vigilant and consider PTB in their differential diagnosis of COVID-19 alongside the possibility of dual infection with COVID-19 and PTB, especially among people living with HIV. It is equally important that patients with confirmed or presumptive PTB symptoms be prioritised for COVID-19 testing.

TB and COVID-19 could result in poorer treatment outcomes, especially if TB treatment is interrupted. Another danger is the inadvertent de-prioritisation of TB care if the health system becomes inundated with people experiencing severe acute respiratory syndrome from infection with SARS-CoV-2. We run the risk of amplifying the effect when people with PTB return to communities without adequate treatment, with potential consequences well beyond the COVID-19 pandemic. It therefore behoves us as epidemiologists, clinicians and citizens to act now to stem the tide of COVID-19

Author contributions. JB researched and drafted the manuscript. TM and GS contributed to the concept of the manuscript and critically edited the content. SM, ZS, MP and AD critically edited the manuscript content.

J Boffa
McGill International TB Centre, McGill University, Montreal, Canada; and Centre for Rural Health, School of Nursing and Public Health, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
jody.boffa@mail.mcgill.ca

T Mhlaba
Department of Public Health Medicine, School of Nursing and Public Health, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa

G Sulis
McGill International TB Centre, McGill University, Montreal, Canada

S Moyo
Social Aspects of Public Health, Faculty Health Sciences, University of Cape Town, South Africa

Z Sifumba
St Andrews Hospital, Harding, KwaZulu-Natal, South Africa

M Pai
McGill International TB Centre, McGill University, Montreal, Canada

A Daftary
Faculty of Health, York University, Toronto, Canada; and Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa